The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts
|
|
- Ezra Sullivan
- 6 years ago
- Views:
Transcription
1 The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts Claudia Bruedigam, Ph.D Gordon and Jessie Gilmour Leukaemia Research Laboratory Headed by A/Professor Steven Lane
2 Telomerase is activated to maintain the long-term replicative potential in most cancers including AML Telomerase is overexpressed in most AML Roth et al., Leukemia 23 AML oncogenes activate telomerase Gessner et al., Leukemia 21 Calado and Young, N Engl J Med 29 LSC have shortened telomeres and increased telomerase activity Drummond et al., Leukemia 25, Bernard et al., Leukemia 29 Genetic depletion of telomerase eradicates LSC upon enforced replication via cell cycle arrest and apoptosis Bruedigam et al., Cell Stem Cell 214 Bruedigam et al., Cell Stem Cell 214- QIMR Berghofer Medical Research Institute 2
3 Imetelstat (JNJ ) is a competitive inhibitor of telomerase activity Imetelstat is a covalently lipidated 13- mer oligonucleotide that binds the RNA template of telomerase Herbert et al., Oncogene 25 Imetelstat induced molecular and complete hematological responses in essential thrombocythemia (89%) Baerlocher et al., NEJM 215 Ruden et al, Cancer Treatment Reviews 213 Imetelstat showed efficacy in myelofibrosis (complete or partial remission in 21%) Tefferi et al., NEJM 215 Phase II / III trial to evaluate imetelstat in low or intermediate-1 risk myelodysplastic syndrome NCT QIMR Berghofer Medical Research Institute 3
4 Generating an AML patient-derived xenograft inventory Primary AML patient sample Ficoll separation CD3 depletion Blast morphology (Wright-Giemsa: peripheral blood) Donor chimerism [%] Engraftment (Peripheral blood donor chimerism) engrafted not engrafted ongoing Sublethal irradiation (2.8 Gy) AML marker expression (Bone marrow and spleen) Weeks post-transplant NSGS Engraftment AML symptoms hcd45 hgpr mcd hcd45 hcd34 hcd hcd hcd45 Percent survival 1 5 Survival Individual samples tested (#): 35 Engraftment success rate (%): 72 Median survival (days): Days post-transplant QIMR Berghofer Medical Research Institute 4
5 Preclinical testing of imetelstat in AML PDX Age at diagnosis Gender Primary or serial AML patient sample 1 15 Age at diagnosis [years] # AML patient samples 1 5 male female Sublethal irradiation (2.8 Gy) NSGS (CD3 depletion) # AML patient samples ELN prognosis (Doehner et al., Blood 21 Alpermann et al., Blood 211) adverse intermediate 2 intermediate 1 favorable (Check peripheral blood donor chimerism) Randomize Imetelstat (15 mg / kg bw) or PBS tiw ip Engraftment AML symptoms QIMR Berghofer Medical Research Institute 5
6 Imetelstat prolongs overall survival in AML PDX Overall survival Percent survival 1 5 PBS Imetelstat Days post-start of treatment Median survival: PBS: 83 Imetelstat: 153 p <.1 QIMR Berghofer Medical Research Institute 6
7 Imetelstat suppresses AML expansion in 14 out of 15 PDX Overall survival AML expansion Percent survival Days post-start of treatment Median survival: PBS: 83 Imetelstat: 153 PBS Imetelstat Peripheral blood donor chimerism [%] PBS Imetelstat p < Days post-start of treatment QIMR Berghofer Medical Research Institute 7
8 AML PDX can be separated into two groups with distinct response to imetelstat therapy Sustained responders Poor responders Percent survival 1 5 p <.1 Percent survival 1 5 p =.3351 PBS Imetelstat Days post-start of treatment Days post-start of treatment # AML patient samples ELN prognosis (Sustained responders) favorable adverse intermediate 2 intermediate 1 # AML patient samples ELN prognosis (Poor responders) QIMR Berghofer Medical Research Institute 8
9 Next generation sequencing reveals baseline mutations in AML patient samples # AML patient samples NPM1 DNMT3A IDH2 FLT3 NRAS KRAS TET2 ETV6 EZH2 FANCM MKI67 PTPN11 RAD21 SRSF2 WT1 APC ARID1B ASXL1 AXL BCOR BCORL1 BRCA1 BRD4 CD36 CXCR4 ECT2L ESR1 ETS1 FANCF JAK3 KDM2B MAGED1 MSH2 MSH3 PARK2 PLCG2 PTPRD RAD54L RUNX1 SMC1A HemePACT assay in collaboration with Stanley Chun-Wei Lee and Omar Abdel-Wahab, MSKCC SMO STAG1 TLL2 TRAF2 U2AF1 ZNF73 QIMR Berghofer Medical Research Institute 9
10 # AML patient samples The identity and distribution of mutations in selected PDX reflects larger AML cohorts NPM1 DNMT3A IDH2 A No. of Unique Patients with Driver Mutation FLT3 NRAS KRAS TET2 ETV6 EZH2 FANCM MKI67 PTPN11 RAD21 SRSF2 WT1 APC ARID1B ASXL1 AXL BCOR BCORL1 FLT3 NPM1 ELN favorable risk ELN intermediate-i risk ELN intermediate-ii risk ELN adverse risk DNMT3A NRAS complex TET2 7/7q +8/8q IDH2 CEBPA RUNX1 PTPN11 5/5q IDH1 TP53 SRSF2 inv(16) MLL WT1 KRAS 17/17p /11q t(6;9) ELN risk not available ASXL1 KIT STAG2 t(15;17) t(8;21) t(11q23;x) RAD21 9q abn3q 12/12p EZH2 PHF6 Y SF3B1 +21CBL Papaemmanuil et al., NEJM 216 BRCA1 BRD4 CD36 CXCR4 ECT2L ESR1 ETS1 FANCF JAK3 KDM2B MAGED1 MSH2 MSH3 PARK2 PLCG2 PTPRD RAD54L RUNX1 HemePACT assay in collaboration with Stanley Chun-Wei Lee and Omar Abdel-Wahab, MSKCC KDM5A MLL2 ZRSR2 JAK2 CREBBP KDM6A MLL3 BRAF FBXW7 ATRX CUX1 RB1 MPL PRPF4B PTEN U2AF1 BCOR GATA2 NF1 2/2q CDKN2A GNAS MLL5 SF1 U2AF2 CBLB IKZF1 SF3A1 SH2B3 4/4q MYC /18q inv(3)/t(3;3) EP3 ETV6 +13 SMC1A SMO STAG1 TLL2 TRAF2 U2AF1 ZNF73 QIMR Berghofer Medical Research Institute 1
11 Imetelstat response is correlated with a distinct mutational landscape Mutations occuring in both sustained and poor responders NPM1 DNMT3A IDH2 KRAS EZH2 PTPN11 SRSF2 Poor responders Sustained responders QIMR Berghofer Medical Research Institute 11
12 Imetelstat response is correlated with a distinct mutational landscape Mutations occuring in both sustained and poor responders Mutations occuring exclusively in sustained responders NPM1 DNMT3A IDH2 KRAS EZH2 PTPN11 SRSF2 FLT3 NRAS TET2 RAD21 ARID1B CD36 ECT2L JAK3 KDM2B MAGED1 MSH2 MSH3 PARK2 PTPRD RAD54L RUNX1 SMC1A STAG1 ZNF73 Poor responders Sustained responders QIMR Berghofer Medical Research Institute 12
13 Imetelstat response is correlated with a distinct mutational landscape Mutations occuring in both sustained and poor responders Mutations occuring exclusively in sustained responders Mutations occuring exclusively in poor responders NPM1 DNMT3A IDH2 KRAS EZH2 PTPN11 SRSF2 FLT3 NRAS TET2 RAD21 ARID1B CD36 ECT2L JAK3 KDM2B MAGED1 MSH2 MSH3 PARK2 PTPRD RAD54L RUNX1 SMC1A STAG1 ZNF73 ETV6 FANCM MKI67 WT1 APC ASXL1 AXL BCOR BCORL1 BRCA1 BRD4 CXCR4 ESR1 ETS1 FANCF PLCG2 SMO TLL2 TRAF2 U2AF1 Poor responders Sustained responders QIMR Berghofer Medical Research Institute 13
14 Gene ontology analysis of mutually exclusive mutations reveals distinct molecular pathways postreplication repair double-strand break repair response to ionizing radiation DNA recombination chromosome segregation response to radiation DNA repair response to DNA damage stimulus response to abiotic stimulus DNA metabolic process cell cycle process cellular response to stress apoptosis programmed cell death cell death death cell cycle Sustained responders Fold enrichment regulation of myeloid cell differentiation positive regulation of cell differentiation pattern specification process Pathways in cancer immune system development positive regulation of developmental process chromosome organization regulation of programmed cell death regulation of cell death Poor responders Fold enrichment QIMR Berghofer Medical Research Institute 14
15 Gene ontology analysis of mutually exclusive mutations reveals distinct molecular pathways Sustained responders 1. DNA repair postreplication repair double-strand break repair response to ionizing radiation DNA recombination chromosome segregation response to radiation DNA repair response to DNA damage stimulus response to abiotic stimulus DNA metabolic process cell cycle process cellular response to stress apoptosis programmed cell death cell death death cell cycle Fold enrichment Poor responders regulation of myeloid cell differentiation positive regulation of cell differentiation pattern specification process Pathways in cancer immune system development positive regulation of developmental process chromosome organization regulation of programmed cell death regulation of cell death Fold enrichment QIMR Berghofer Medical Research Institute 15
16 Gene ontology analysis of mutually exclusive mutations reveals distinct molecular pathways Sustained responders 1. DNA repair 2. Cell cycle postreplication repair double-strand break repair response to ionizing radiation DNA recombination chromosome segregation response to radiation DNA repair response to DNA damage stimulus response to abiotic stimulus DNA metabolic process cell cycle process cellular response to stress apoptosis programmed cell death cell death death cell cycle Fold enrichment Poor responders regulation of myeloid cell differentiation positive regulation of cell differentiation pattern specification process Pathways in cancer immune system development positive regulation of developmental process chromosome organization regulation of programmed cell death regulation of cell death Fold enrichment QIMR Berghofer Medical Research Institute 16
17 Gene ontology analysis of mutually exclusive mutations reveals distinct molecular pathways Sustained responders 1. DNA repair 2. Cell cycle postreplication repair double-strand break repair response to ionizing radiation DNA recombination chromosome segregation response to radiation DNA repair response to DNA damage stimulus response to abiotic stimulus DNA metabolic process cell cycle process cellular response to stress apoptosis programmed cell death cell death death cell cycle Fold enrichment 3. Development and differentiation regulation of myeloid cell differentiation positive regulation of cell differentiation pattern specification process Pathways in cancer immune system development positive regulation of developmental process chromosome organization regulation of programmed cell death regulation of cell death Poor responders Fold enrichment QIMR Berghofer Medical Research Institute 17
18 Gene ontology analysis of mutually exclusive mutations reveals distinct molecular pathways Sustained responders 1. DNA repair 2. Cell cycle postreplication repair double-strand break repair response to ionizing radiation DNA recombination chromosome segregation response to radiation DNA repair response to DNA damage stimulus response to abiotic stimulus DNA metabolic process cell cycle process cellular response to stress apoptosis programmed cell death cell death death cell cycle Fold enrichment 3. Development and differentiation 4. Pathways in cancer regulation of myeloid cell differentiation positive regulation of cell differentiation pattern specification process Pathways in cancer immune system development positive regulation of developmental process chromosome organization regulation of programmed cell death regulation of cell death Poor responders Fold enrichment QIMR Berghofer Medical Research Institute 18
19 Imetelstat induces DNA damage and loss of quiescence in LSC in vivo AML patient sample Sublethal irradiation (2.8 Gy) NSGS H2AX MFI in G1 LSC [normalized to PBS] H2AX p <.1 LSC in G [%] G p =.2 AML-16 AML-5 AML-18 (Check peripheral blood donor chimerism) Randomize H2AX. PBS Imetelstat PBS Imetelstat PBS Imetelstat Imetelstat (15 mg / kg bw) or PBS tiw ip Endpoint analysis at disease onset of PBS group QIMR Berghofer Medical Research Institute 19
20 Modelling normal human hematopoiesis Cord blood donor sample Sublethal irradiation (2.8 Gy) CD34 enrichment NSG Imetelstat (15 mg / kg bw) or PBS tiw ip 1 weeks Human hematopoiesis phenotype endpoint analysis QIMR Berghofer Medical Research Institute 2
21 Imetelstat primarily depletes B lymphocytes Cord blood donor sample Donor chimerism (Spleen) B cells (Spleen) Myeloid cells (Spleen) Sublethal irradiation (2.8 Gy) NSG CD34 enrichment Imetelstat (15 mg / kg bw) or PBS tiw ip 1 weeks Donor chimerism [%] ** **** Donor 1: PBS Donor 1: Imetelstat Donor 2: PBS Donor 2: Imetelstat CD19+ [% of viable CD45+] * p =.8 Donor 1: PBS Donor 1: Imetelstat Donor 2: PBS Donor 2: Imetelstat CD33+ [% of viable CD45+] * p =.667 Donor 1: PBS Donor 1: Imetelstat Donor 2: PBS Donor 2: Imetelstat Human hematopoiesis phenotype endpoint analysis QIMR Berghofer Medical Research Institute 21
22 Human cord blood - derived stem cells are preserved during imetelstat treatment Cord blood donor sample Sublethal irradiation (2.8 Gy) NSG CD34 enrichment Imetelstat (15 mg / kg bw) or PBS tiw ip 1 weeks Donor chimerism [%] Donor chimerism (Bone marrow) ** **** Donor 1: PBS Donor 1: Imetelstat Donor 2: PBS Donor 2: Imetelstat CD34+CD38- from CD45+ % HSC (Bone marrow) Donor 1: PBS Donor 1: Imetelstat Donor 2: PBS Donor 2: Imetelstat MFI H2AX in G1 CD34+CD H2AX in HSC (Bone marrow) Donor 1: PBS Donor 1: Imetelstat Donor 2: PBS Donor 2: Imetelstat Human hematopoiesis phenotype endpoint analysis QIMR Berghofer Medical Research Institute 22
23 Summary: Preclinical efficacy of imetelstat in AML PDX Imetelstat is effective in a subgroup (6%) of AML patient samples Imetelstat prevents expansion and prolongs overall survival in AML PDX (PBS: 83 days; Imetelstat: 153 days post-start of treatment) Sustained responses to imetelstat are correlated with favorable cytogenetics, mutational profiles of DNA damage and activation of DNA damage response pathways This study has generated preclinical data to inform clinical trials and provide a precision approach to targeted therapies in patients with AML QIMR Berghofer Medical Research Institute 23
24 Acknowledgements QIMR Berghofer Medical Research Institute Gordon and Jessie Gilmour Leukaemia Research Lab - Steven Lane - Brad Wackrow - Axia Song - Amy Porter - Joanne Sutton - Sebastien Jacquelin - Therese Vu - Rebecca Austin - Emma Dishington - Solene Guignes - Jasmin Straube - FACS Core: Grace, Paula, Michael - Animal House: Sue, Jonathan, Dave - Statistics: Leesa, Louise, Mandy, Peter Royal Brisbane and Women s Hospital - Patients and health professionals Memorial Sloan Kettering Institute - Omar Abdel-Wahab - Stanley Chun-Wei Lee The University of Queensland Diamantina Institute, Translational Research Institute - Andrew Moore The University of New South Wales - Richard Lock The University of South Australia - Hamish Scott Funding NHMRC Leukaemia Foundation of Australia Cure Cancer Australia Rio Tinto Ride to Conquer Cancer Janssen (research funding agreement) QIMR Berghofer Medical Research Institute 24
Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationSupplementary Information
Supplementary Information Table of Contents Supplementary methods... 2 Figure S1 - Variable DNA yield proportional to bone marrow aspirate cellularity.... 3 Figure S2 - Mutations by clinical ontogeny group....
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationThe Evolving Role of Transplantation for MPN
The Evolving Role of Transplantation for MPN (PMF, PV, ET) H.Joachim Deeg MD Fred Hutchinson Cancer Research Center, University of Washington, Seattle WA, SCCA jdeeg@fhcrc.org 10 th J. Niblack Conference
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationNext generation sequencing analysis - A UK perspective. Nicholas Lea
Next generation sequencing analysis - A UK perspective Nicholas Lea King s HMDC LMH is part of an integrated pathology service at King s Haematological Malignancy Diagnostic Centre (HMDC) HMDC serves population
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationManagement of Myelodysplastic Syndromes
Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A
More information7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution?
New Directions in Aplastic Anemia: What's on the Horizon? Amy E. DeZern, MD; MHS Assistant Professor Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives
More informationShould Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationDISCLOSURE Luca Malcovati, MD. No financial relationships to disclose
ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE
More informationMutational Impact on Diagnostic and Prognostic Evaluation of MDS
Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Papaemmanuil Lab, Computational Oncology, MSKCC MDS Foundation ASH 2018 Symposium Disclosure Research funds provided by
More informationMyelodysplastic syndromes and the new WHO 2016 classification
Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital
More informationSupplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
More informationLaboratory Service Report
Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Models
Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Models 4 th Annual International Erdheim-Chester Disease Medical Symposium Paris, France September 15, 2016 Benjamin
More informationGetting started in research
Getting started in research Assoc. Prof. Steven Lane MBBS (Hons) PhD FRACP FRCPA Team Head: Translational Leukaemia Research Laboratory Queensland Institute of Medical Research Clinical Haematologist:
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationJuan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1
Juan Ma 1, Jennifer Dunlap 2, Lisong Shen 1, Guang Fan 2 1 Xin Hua Hospital, Shanghai, China 2 Oregon Health & Science University, Portland, OR, United States AML is a hematopoietic neoplasms characterized
More informationPDX Tumor Biology Pla0orms for Drug Advancement Neal Goodwin, Ph.D. Vice President Corporate Research & Development
PDX Tumor Biology Pla0orms for Drug Advancement Neal Goodwin, Ph.D. Vice President Corporate Research & Development ngoodwin@championsoncology.com +1-530-392-2741 Champions Oncology: Global provider of
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationPediatric Oncology & Pathology Services
Pediatric Oncology & Pathology Services Anatomic Pathology Flow Cytometry Cytogenetics Pharma Services Diagnostic, Prognostic, Predictive, and Predisposition Testing Pediatric Oncology & Pathology Services
More informationDeep Learning Analytics for Predicting Prognosis of Acute Myeloid Leukemia with Cytogenetics, Age, and Mutations
Deep Learning Analytics for Predicting Prognosis of Acute Myeloid Leukemia with Cytogenetics, Age, and Mutations Andy Nguyen, M.D., M.S. Medical Director, Hematopathology, Hematology and Coagulation Laboratory,
More informationMyelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie
Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationIntroduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
More informationChanging AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike
More informationEnhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine
Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the
More informationPrecision Medicine and Molecular Testing.
Precision Medicine and Molecular Testing. David A. Sallman, MD Assistant Member Department of Malignant Hematology Moffitt Cancer Center david.sallman@moffitt.org Disclosures Research funding for Celgene
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationabstract n engl j med 374;23 nejm.org June 9,
The new england journal of medicine established in 1812 June 9, 2016 vol. 374 no. 23 Genomic Classification and Prognosis in Acute Myeloid Leukemia Elli Papaemmanuil, Ph.D., Moritz Gerstung, Ph.D., Lars
More informationIdentification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins
Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular
More informationMyelodysplastic syndrome is a highly heterogeneous hematopoietic
SHORT COMMUNICATION Clinical Characteristics and Prognosis of 48 Patients with Mutations in Myelodysplastic Syndrome Yulu Tian #, Ruijuan Zhang #, Linhua Yang* Yang L. Clinical Characteristics and Prognosis
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationEnhancing Assessment of Myeloid Disorders in the Era of Precision Medicine
Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center Objectives
More informationEnhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine
Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center How the
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationGenetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies
Genetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies Raajit Rampal, MD, PhD Assistant Attending Physician Leukemia
More informationAML Genomics 11/27/17. Normal neutrophil maturation. Acute Myeloid Leukemia (AML) = block in differentiation. Myelomonocy9c FAB M5
AML Genomics 1 Normal neutrophil maturation Acute Myeloid Leukemia (AML) = block in differentiation AML with minimal differen9a9on FAB M1 Promyelocy9c leukemia FAB M3 Myelomonocy9c FAB M5 2 1 Principle
More informationASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationClassification and risk assessment in AML: integrating cytogenetics and molecular profiling
ACUTE MYELOID LEUKEMIA: HOW CAN WE IMPROVE UPON STANDARD THERAPY? Classification and risk assessment in AML: integrating cytogenetics and molecular profiling Matahi Moarii and Elli Papaemmanuil Department
More informationPrecision Oncology: Experience at UW
Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,
More informationPublished Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.
Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationADRL Advanced Diagnostics Research Laboratory
ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New
More informationMolecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong
More informationWest Midlands Regional Genetics Laboratory
West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationWe are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university
Enhancing Assessment of Leukemia with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical i l Molecular l Laboratory City of Hope National Medical Center How the Expert Treat Hematologic
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationMolecular Minimal Residual Disease in Acute Myeloid Leukemia
Original Article Molecular Minimal Residual Disease in Acute Myeloid Leukemia M. Jongen Lavrencic, T. Grob, D. Hanekamp, F.G. Kavelaars, A. al Hinai, A. Zeilemaker, C.A.J. Erpelinck Verschueren, P.L. Gradowska,
More informationPublished Ahead of Print on June 22, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on June 22, 2017, as doi:10.3324/haematol.2017.166173. Copyright 2017 Ferrata Storti Foundation. Molecular analysis of myelodysplastic syndrome with isolated del(5q) reveals a
More informationChanging the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle
Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center
More informationMolecular Minimal Residual Disease in Acute Myeloid Leukemia
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 Molecular Minimal Residual Disease in Acute Myeloid Leukemia Jongen-Lavrencic,
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationBHS Annual Meeting
BHS Annual Meeting 2014 01.02.2014 Implementing next-generation deepsequencing assays in diagnostic algorithms in hematological malignancies Dr. Alexander Kohlmann Medical Need for Molecular Characterization
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationACTIVITY 2: EXAMINING CANCER PATIENT DATA
OVERVIEW Refer to the Overview of Cancer Discovery Activities for Key Concepts and Learning Objectives, Curriculum Connections, and Prior Knowledge, as well as background information, references, and additional
More informationCurrent Techniques in Molecular Biology Friedel Nollet, Ph.D.
Current Techniques in Molecular Biology Friedel Nollet, Ph.D. Molecular Biology and Cytometry course May 16-17, 2013 Mol, SCK-CEN, Belgium Sanger DNA sequencing Kary Mullis received a Nobel Prize in chemistry
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationObjectives and Financial Disclosure
Enhancing Assessment of Leukemia and Lymphoma with Next Generation Sequencing Michelle Afkhami, M.D. Medical Director, Clinical Molecular Laboratory Assistant Professor, Department of Pathology City of
More informationJocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic
Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationSUPPLEMENTAL APPENDIX METZELER ET AL.: SPECTRUM AND PROGNOSTIC RELEVANCE OF DRIVER GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA
SUPPLEMENTAL APPENDIX TO METZELER ET AL.: SPECTRUM AND PROGNOSTIC RELEVANCE OF DRIVER GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA SUPPLEMENTAL METHODS Treatment protocols In the AMLCG-1999 trial 1-3 (clinicaltrials.gov
More informationSession 4: Summary and Conclusions
Session 4: Summary and Conclusions Total cases in Session 4 Myeloproliferative neoplasms 16 cases Oral #300 (CEL, NOS) Mastocytosis 2 cases Oral #156 (SM-AHN) Myeloid/lymphoid neoplasms with eosinophilia
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationMolecular Genetic Testing to Predict Response to Therapy in MDS
Molecular Genetic Testing to Predict Response to Therapy in MDS Rafael Bejar MD, PhD Bone Marrow Failure Disease Scientific Symposium Rockville, MD March 18 th, 2016 Overview Response Criteria Lenalidomide
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationOverview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology
Overview Next Generation Sequencing and Precision Medicine in Hematological Malignancies Sharathkumar Bhagavathi, MD University of Iowa Carver College of Medicine NGS as a genotyping platform in hematopathology
More informationMyelodysplastic syndromes
Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.
More informationAbnormal blood test Y E A R S. Diagnosis of MDS
Abnormal blood test 3 Y E A R S Diagnosis of MDS Demographics of Germany [90 2050] and Europe Italy Germany Spain Austria Greece eu5 Countrybyrankorder in203 Finland Portugal Belgium France UK Netherlands
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationCBL and EZH2 as new molecular markers in MPN
CBL and EZH2 as new molecular markers in MPN Andy Chase University of Southampton and Wessex Regional Genetics Laboratory Salisbury, UK Munich 2011 * Myeloproliferative neoplasms MDS/MPN Myelodysplastic
More informationMayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
REGULAR ARTICLE Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models Animesh Pardanani, 1 Sahrish Shah, 1 Francesco Mannelli, 2 Yoseph C. Elala, 1 Paola Guglielmelli,
More informationASH 2014 Analyst & Investor Event
ASH 2014 Analyst & Investor Event December 8, 2014 John A. Scarlett, M.D. President & CEO, Geron Corporation Steven Lane, M.D., Ph.D. Queensland Institute of Medical Research Forward-Looking Statements
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More informationWhat is the status of the technologies of "precision medicine?
Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.
More informationClinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD
Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationTargeted next-generation sequencing in blast phase myeloproliferative neoplasms
REGULAR ARTICLE Targeted next-generation sequencing in blast phase myeloproliferative neoplasms Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber,
More information